Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Net Cash Flow (2020 - 2025)

Treace Medical Concepts (TMCI) has disclosed Net Cash Flow for 6 consecutive years, with $3.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow rose 497.63% year-over-year to $3.0 million, compared with a TTM value of -$642000.0 through Dec 2025, up 60.66%, and an annual FY2025 reading of -$642000.0, up 60.66% over the prior year.
  • Net Cash Flow was $3.0 million for Q4 2025 at Treace Medical Concepts, up from -$366000.0 in the prior quarter.
  • Across five years, Net Cash Flow topped out at $103.4 million in Q2 2021 and bottomed at -$69.1 million in Q4 2022.
  • Average Net Cash Flow over 5 years is -$368550.0, with a median of -$2.7 million recorded in 2021.
  • The sharpest move saw Net Cash Flow skyrocketed 34791.28% in 2021, then tumbled 1804.94% in 2022.
  • Year by year, Net Cash Flow stood at -$3.6 million in 2021, then crashed by 1804.94% to -$69.1 million in 2022, then skyrocketed by 108.26% to $5.7 million in 2023, then plummeted by 113.32% to -$760000.0 in 2024, then soared by 497.63% to $3.0 million in 2025.
  • Business Quant data shows Net Cash Flow for TMCI at $3.0 million in Q4 2025, -$366000.0 in Q3 2025, and -$5.3 million in Q2 2025.